surpass tirzepatide Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial Tirzepatide Once Weekly in Children
Pay in 4 interest-free payments of $7.24 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 30 - Oct 5













![Dansyl-X, SE [6-((5-Dimethylaminonaphthalene-1-Sulfonyl)amino)Hexanoic Acid, SE]](https://www.anaspec.com/assets/d2ec8f85-4de6-4ca4-9acc-d80b67f45811/1500x1500/as-81214-img-en-as-81214-01.jpg)








